The U.S. market for disease management (DM) services is anticipated to reach $30 billion by 2013 as a result of the nation’s aging population, increased incidence of chronic diseases, increased enrollment in Medicare and Medicaid programs, and continuing pressure to contain health care costs.

The retail pharmacy industry is in a key position to take advantage of disease management growth trends and deliver DM services effectively and profitably, according to "Disease Management and Retail Pharmacies: A Convergence Opportunity," a new paper from the Deloitte Center for Health Solutions, part of Deloitte LLP.

The convergence of disease management and retail pharmacies makes sense: It leverages key assets in which retail pharmacies have already invested – convenient locations, 24-7 operating models at many locations, prescription fulfillment services, consumer marketing, brand positioning, retail clinics, and health and personal care products.

The current DM operating model is labor-intense and nonscalable, so innovations that leverage technology for care coordination are essential for future success. Retail pharmacy chains should consider collaborating with health plans or disease management vendors as a potential market entry strategy.

To read the full report, please download the PDF attached below.

Series on “Disruptive Innovations” in Health Care
This paper is part of a series of reports by the Deloitte Center for Health Solutions about “disruptive innovations” in health care. Learn more about the series. 

Subscribe to Center research